Raymond Anderson
About Raymond W. Anderson
Raymond W. Anderson (age 83) is an independent director of Monopar Therapeutics since April 2017, serving as Audit Committee Chair, Compensation Committee Chair, CG&N Committee member, and Plan Administrator Committee member. He is an “audit committee financial expert” under SEC and Nasdaq rules, with prior senior finance roles in biopharma and degrees from Harvard (MBA), George Washington University (MS), and the U.S. Military Academy (BS) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| BioMarin Pharmaceutical | Chief Operating Officer; Chief Financial Officer | June 1998–January 2002 | Senior financial and operations leadership |
| Transurgical, Inc. | Chief Financial Officer | Not disclosed | Private ultrasound surgical system company finance leadership |
| Dow Pharmaceutical Sciences | CFO & VP Finance/Admin; Managing Director | July 2003–June 2010; MD Jan 2009–Jun 2010 | Led finance/admin; later Managing Director |
| Raptor Pharmaceuticals | Director; Audit Committee Chair; Compensation Committee member | 2006–2016 | Chaired Audit; served on Compensation |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Raptor Pharmaceuticals (public, acquired 2016) | Director; Audit Chair; Compensation member | 2006–2016 | Only prior public company board disclosed in MNPR proxy |
Board Governance
-
Committee assignments and chair roles:
- Audit Committee: Chair; independent; designated financial expert
- Compensation Committee: Chair
- Corporate Governance & Nominating (CG&N): Member
- Plan Administrator Committee: Member (committee has no charter)
-
Independence: Board determined Anderson independent under Nasdaq standards .
-
Attendance and engagement:
- 2024 meetings: Board 6; Audit 5; Compensation 1; CG&N 1; Plan Administrator Committee 4 unanimous written actions .
- All directors attended at least 75% of Board and applicable committee meetings in 2024; 5 of 6 directors attended the 2024 annual meeting .
-
Tenure on MNPR board: Director since April 2017 .
Fixed Compensation
| Component | 2024 Amount (USD) |
|---|---|
| Non-Employee Board Member Base Fee | 40,000 |
| Audit Committee Chair | 15,000 |
| Compensation Committee Chair | 12,500 |
| CG&N Committee Member | 5,000 |
| Total Fees Earned (Anderson) | 72,500 |
Notes:
- Fees paid quarterly in arrears .
- Non-equity fee schedule unchanged from 2023; long-term equity compensation is reviewed annually using Black-Scholes and peer group consideration .
Performance Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Stock Awards ($) | 32,020 | 0 (none granted) |
| Option Awards ($) | 32,021 | 0 (none granted) |
| RSUs Outstanding (year-end) | None | None |
| Options Outstanding (year-end, fully vested) | 86,271 | 17,256 |
Performance metric framework tied to director compensation: Not disclosed for directors in the proxy statements; equity awards valuation uses Black-Scholes, with peer group review for long-term equity compensation when applicable .
Other Directorships & Interlocks
| Company | Role | Committees | Interlocks/Notes |
|---|---|---|---|
| Raptor Pharmaceuticals | Director | Audit Chair; Compensation member | Prior public biopharma board (2006–2016) |
No other current public company directorships for Anderson are disclosed in MNPR’s 2025 proxy biography .
Expertise & Qualifications
- Audit committee financial expert; extensive biopharma finance and operations experience .
- Education: MBA (Harvard), MS Administration (George Washington University), BS Engineering (U.S. Military Academy) .
Equity Ownership
| As-of Date | Shares Beneficially Owned | Percent of Class | Options included in beneficial ownership (vested or vesting within 60 days) | Notes |
|---|---|---|---|---|
| June 14, 2024 | 113,134 | * (less than 1%) | 86,271 | Beneficial ownership % based on 17,568,175 shares outstanding |
| April 4, 2025 | 25,470 | * (less than 1%) | 20,097 | Beneficial ownership % based on 6,115,214 shares outstanding |
Additional ownership alignment details:
- As of year-end 2023 and 2024, non-employee director options were fully vested; no unvested RSUs outstanding .
- No disclosure of pledged shares by Anderson; hedging policy section exists in the proxy table of contents (details not enumerated in excerpts) .
Governance Assessment
- Board effectiveness and independence: Anderson chairs two key committees (Audit and Compensation) and is designated an audit committee financial expert, supporting oversight quality in financial reporting and executive pay . Attendance thresholds were met across the Board in 2024, with robust committee activity (5 Audit meetings) indicating active engagement .
- Compensation and alignment signals: In 2024, director compensation shifted to cash fees only with no stock or option awards, while options at year-end were fully vested and RSUs were none; in 2023 directors received both stock and option awards, suggesting reduced at-risk equity in 2024 for non-employee directors . Fee components align precisely with Anderson’s chair and membership roles (total $72,500) .
- Conflicts and related-party exposure: The company reports no related-party transactions since January 2024; Audit Committee oversees approvals of any related party transactions per charter, reducing conflict risk .
- Risk indicators:
- RED FLAGS: None disclosed regarding related-party transactions, pledging, or option repricing for directors in the provided materials .
- Process safeguards: Independent status affirmed; formal charters for Audit and Compensation committees; CG&N oversight of board composition and independence .
- Shareholder oversight context: Advisory votes on executive compensation and hedging policy sections are included in proxy materials (contextual governance mechanisms), though outcomes and policy specifics are not detailed in excerpts .